Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus I-125 Seeds in TACE-Refractory HCC
NCT05608213Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Nov 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Overall Survival at 4 years. Started Nov 2022; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05608213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608213.